Abstract Library

#3016 DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance

Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liverani C

Authors: Liverani C, Bongiovanni A, Pieri F, Foca F, Ravaioli S,

Keywords: DLL3, RB1, prognostic biomarker, GEP-NEN,

#2973 Robustness of Radiomic Features in 68Ga-DOTATOC PET/CT: A Monocentric Experience for Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of malignancies with varied histology, localization and behaviour.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liberini V

Authors: Liberini V, De Santi B, Gallio E, Rampado O, Dionisi B,

Keywords: NET, heterogeneous, 68Ga-DOTATOC, contouring methods, LIFEx, radiomic, texture features, PET/CT,

#2951 Analysis of Discordance between Biopsy Grade and Surgical Pathology Grade in Resected PanNEN Patients

Introduction: In PanNEN cases, treatment strategies are decided by tumor localization, volume and grade. In unresectable or metastatic cases, tumor grade is determined by biopsy specimen obtained from EUS-FNA and diagnostic accuracy of biopsy according to WHO classification 2017 is important for decision making of treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Nakano K, Masui T, Yogo A, Uchida Y, Nagai K,

Keywords: PanNEN, WHO classification 2017, EUS-FNA, Ki-67, biopsy, surgical pathology, discordance,

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#2740 Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report

Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Della Torre S

Authors: Lombardi P, Grandi S, Marinelli M, Manara M, Della Torre S,

Keywords: rectal nec, net, chemotherapy, metastatic disease,